Welcome!
Home GuocoLand
Broker's Calls
Sole bid for Marina Gardens site may help lift Guocoland's RNAV by 3.5%
The project might add up to 20 cents to Guocoland's RNAV per share of $5.70
January 19, 2024
Billion Dollar Club 2023
GuocoLand tops sector as investment properties take root
GuocoLand has shifted its strategy from developing largely residential projects into one that places more emphasis on investment
November 09, 2023
Billion Dollar Club 2023
GuocoLand's 'twin engines' of growth
Emerging from the pandemic, GuocoLand appears to defy the worries of many market-watchers.
November 09, 2023
Results
GuocoLand reports 60% rise in revenue for FY2023, but 44% fall in net profit
GuocoLand reports 60% y-o-y growth in revenue in FY2023, but 44% decline in net profit on impairment and higher interest cost
August 29, 2023
Broker's Calls
DBS prefers CDL and Guocoland, citing strong interest for recent projects
We can sense the continued interest, 'vibe' and 'excitement' amongst buyers
July 03, 2023
Results
GuocoLand reports 1HFY2023 earnings of $59 million
"Despite the multiple headwinds, GuocoLand has been able to increase our revenue and profits and deliver a robust set of results."
January 19, 2023
Broker's Calls
DBS explains what higher interest rates spell for banks and developers CDL, UOL, Guocoland
Households could potentially face $1,000 per month higher mortgage payments on the new rates once loans are refinanced.
November 01, 2022
Property
Gaining an investment foothold
GuocoLand, traditionally a developer of residences, has progressively pivoted towards investment properties
October 04, 2022
Broker's Calls
Analysts identify CDL as their top picks amid the strong new launch sales momentum in Singapore’s residential sector
DBS analysts have also pegged GuocoLand as one of their top sector picks.
September 12, 2022
Broker's Calls
Broker's Digest: Guocoland, Yangzijiang Shipbuilding, Keppel Corp, HRNetGroup, Hyphens Pharma International
Broker's Digest: Guocoland, Yangzijiang Shipbuilding, Keppel Corp, HRNetGroup, Hyphens Pharma International
April 07, 2022